Effect of HIV genotypic drug resistance testing on the management and clinical course of HIV-infected children and adolescents

被引:5
作者
Dehority, W. [1 ]
Deville, J. G. [2 ]
Lujan-Zilbermann, J. [3 ]
Spector, S. A. [4 ]
Viani, R. M. [4 ]
机构
[1] Univ New Mexico, Hlth Sci Ctr, Dept Pediat, Univ New Mexico 1, Albuquerque, NM 87131 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Childrens Hlth Ctr, Dept Pediat, Los Angeles, CA 90095 USA
[3] Univ S Florida, Coll Med, Dept Pediat, Tampa, FL 33606 USA
[4] Univ Calif San Diego, Dept Pediat, Div Infect Dis, Ctr AIDS Res,Sch Med,Rady Childrens Hosp, La Jolla, CA 92093 USA
关键词
HIV; AIDS; drug resistance; antiretroviral therapy; genotype; adherence; pediatrics; adolescents; HIV-1-INFECTED CHILDREN; ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR; PREVALENCE; MUTATIONS; ADHERENCE;
D O I
10.1177/0956462412473958
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The clinical utility of genotypic drug resistance testing (DRT) in HIV-infected children on antiretroviral therapy (ART) is not well understood. HIV-infected patients aged < 19 years undergoing DRT for virological failure were retrospectively enrolled. Indications for DRT and changes in HIV RNA load were recorded. Between January 2000 and December 2006, 57 patients had DRT. The most common indication for DRT was poor ART adherence (57.7% of patients). ART was changed in 50.9% of patients after DRT. Poor adherence was cited by clinicians for not changing ART significantly more often than any other reason (47.3%, P < 0.001). After DRT, significant improvement in HIV RNA load occurred independent of ART changes, though patients whose ART was modified were more likely to become undetectable (31.5% versus 7.0%, P < 0.001). Poor adherence was a significant factor for ordering DRT and for not changing ART in HIV-infected children.
引用
收藏
页码:549 / 553
页数:5
相关论文
共 22 条
[1]   Genotyping for guiding drug choice in human immunodeficiency virus-infected children failing multiple antiretroviral treatment regimens [J].
Badolato, R ;
Schumacher, RF ;
Rodella, E ;
Gargiulo, F ;
Torti, C ;
Notarangelo, LD ;
Duse, M .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (08) :747-749
[2]   HIV-1 drug resistance in newly infected individuals [J].
Boden, D ;
Hurley, A ;
Zhang, LQ ;
Cao, YZ ;
Guo, Y ;
Jones, E ;
Tsay, J ;
Ip, J ;
Farthing, C ;
Limoli, K ;
Parkin, N ;
Markowitz, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12) :1135-1141
[3]   Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy [J].
Brindeiro, PA ;
Brindeiro, RM ;
Mortensen, C ;
Hertogs, K ;
De Vroey, V ;
Rubini, NPM ;
Sion, FS ;
De Sá, CAM ;
Machado, DM ;
Succi, RCM ;
Tanuri, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (12) :4512-4519
[4]  
CALDWELL MB, 1994, MMWR-MORBID MORTAL W, V43, P1
[5]   Response to changes in antiretroviral therapy after genotyping in human immunodeficiency virus-infected children [J].
Cohen, NJ ;
Oram, R ;
Elsen, C ;
Englund, JA .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (07) :647-653
[6]   Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children [J].
Delaugerre, Constance ;
Warszawski, Josiane ;
Chaix, Marie-Laure ;
Veber, Florence ;
Macassa, Eugenia ;
Buseyne, Florence ;
Rouzioux, Christine ;
Blanche, Stephane .
JOURNAL OF MEDICAL VIROLOGY, 2007, 79 (09) :1261-1269
[7]   Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients [J].
Descamps, Diane ;
Lambert-Niclot, Sidonie ;
Marcelin, Anne-Genevieve ;
Peytavin, Gilles ;
Roquebert, Benedicte ;
Katlama, Christine ;
Yeni, Patrick ;
Felices, Mathieu ;
Calvez, Vincent ;
Brun-Vezinet, Francoise .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (03) :585-592
[8]  
Green H, 2006, ANTIVIR THER, V11, P857
[9]  
Hanna GJ, 2001, CLIN INFECT DIS, V32, P774, DOI 10.1086/319231
[10]  
Johnson Victoria A, 2010, Top HIV Med, V18, P156